Develops antibody therapies for Alzheimer's and neurodegenerative disease using a blood-brain-barrier shuttle platform.
Develops antibody therapies for Alzheimer's and neurodegenerative disease using a blood-brain-barrier shuttle platform.
Has no product or revenue, so it relies on the cash it holds and later share sales, and everything depends on whether its lead antibody can reach the brain better than existing treatments. It reached the stock market in 2026 by merging with Cyclerion, an already listed company.
Moat: narrow (IP / patents, process know-how). THETA platform aims for better brain penetration than approved amyloid antibodies, but is unproven in the clinic.
Headquarters: Boston, Massachusetts, US · Founded: 2024 · Employees: 1
Size Korsana Biosciences (KRSA) is a United States Health Care company (Biotechnology) with a market value of $1.52B, the 1968th largest of 3,085 United States companies the cockpit tracks. Shares closed at $33.27 on 18 Nov 2026.
Performance Over six months the shares gained 54.3%, against -6.9% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue fell 64.1% over the last twelve months (peer median +25.4%); the operating margin is -5,277.3% (peer median -5.7%).
Valuation It trades at 1,058.7× enterprise value to sales against a peer median of 10.1× (2nd most expensive of 18).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.02M | $2.07M | $2.00M | $0 | $297,000 |
| Revenue growth | — | +4% | — | -100% | — |
| Gross profit | n/a | n/a | n/a | $0 | $232,000 |
| EBITDA | -$54.1M | -$4.97M | -$3.63M | -$9.65M | -$18.5M |
| Net income | -$52.2M | -$3.53M | -$3.06M | -$21.0M | -$44.1M |
| Free cash flow | -$51.3M | -$3.31M | -$4.33M | -$21.2M | -$40.6M |
| Capital expenditure | $297,000 | $0 | $0 | $0 | $0 |
| Total debt | $1.27M | $0 | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Korsana Biosciences KRSA | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 4.4× | 10.1% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KRSA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.2% | -10.9% | 2nd highest of 21 |
| 6-month return | +54.3% | -6.9% | 2nd highest of 20 |
| Distance from 52-week high | -44.0% | -43.2% | 11th highest of 21 |
| Revenue growth (TTM) | -64.1% | +25.4% | lowest of 19 |
| Operating margin | -5,277.3% | -5.7% | 2nd lowest of 19 |
| EV / Sales | 1,058.7× | 10.1× | 2nd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | 0.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | 4.0× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 3.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | 1,650.2× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |